SAM
SRPT icon

Shell Asset Management’s Sarepta Therapeutics SRPT Stock Holding History

Shell Asset Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$26K Sell
1,350
-1,584
-54% -$28.2K ﹤0.01% 1004
2025
Q2 		$50K Sell
2,934
-628
-18% -$26.8K ﹤0.01% 1145
2025
Q1 		$227K Sell
3,562
-146
-4% -$15.4K 0.01% 740
2024
Q4 		$451K Sell
3,708
-6
-0.2% -$735 0.02% 528
2024
Q3 		$464K Buy
+3,714
New +$513K 0.02% 518
2024
Q1 		$591K Sell
3,740
-375
-9% -$45.9K 0.03% 418
2023
Q4 		$397K Sell
4,115
-1,232
-23% -$118K 0.02% 601
2023
Q3 		$648K Sell
5,347
-93
-2% -$10.5K 0.03% 463
2023
Q2 		$623K Buy
5,440
+1,090
+25% +$141K 0.02% 504
2023
Q1 		$600K Sell
4,350
-15
-0.3% -$1.95K 0.02% 495
2022
Q4 		$566K Sell
4,365
-880
-17% -$102K 0.02% 490
2022
Q3 		$580K Sell
5,245
-1,371
-21% -$138K 0.02% 502
2022
Q2 		$496K Buy
6,616
+1,135
+21% +$83.5K 0.01% 724
2022
Q1 		$428K Sell
5,481
-812
-13% -$62.2K 0.01% 880
2021
Q4 		$567K Buy
6,293
+26
+0.4% +$2.22K 0.01% 844
2021
Q3 		$580K Sell
6,267
-270
-4% -$20.8K 0.01% 801
2021
Q2 		$508K Buy
6,537
+2,860
+78% +$217K 0.01% 911
2021
Q1 		$274K Sell
3,677
-4,099
-53% -$378K 0.01% 1057
2020
Q4 		$1.33M Buy
7,776
+163
+2% +$24.2K 0.03% 450
2020
Q3 		$1.07M Sell
7,613
-1,473
-16% -$224K 0.02% 439
2020
Q2 		$1.46M Buy
9,086
+1,031
+13% +$140K 0.04% 364
2020
Q1 		$788K Sell
8,055
-1,697
-17% -$194K 0.02% 493
2019
Q4 		$1.26M Buy
9,752
+1,842
+23% +$186K 0.03% 465
2019
Q3 		$596K Sell
7,910
-4,622
-37% -$546K 0.01% 804
2019
Q2 		$1.9M Sell
12,532
-151
-1% -$18.4K 0.04% 361
2019
Q1 		$1.51M Buy
12,683
+5,959
+89% +$766K 0.03% 410
2018
Q4 		$734K Sell
6,724
-600
-8% -$75K 0.02% 662
2018
Q3 		$1.18M Hold
7,324
– – 0.02% 574
2018
Q2 		$968K Sell
7,324
-391
-5% -$36.9K 0.02% 698
2018
Q1 		$572K Hold
7,715
– – 0.01% 876
2017
Q4 		$429K Buy
+7,715
New +$409K 0.01% 949

Other funds holding SRPT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Shell Asset Management's SRPT Position: Q3 2025 in Review

Shell Asset Management reduced its Sarepta Therapeutics (SRPT) stake by 54% in Q3 2025, selling an estimated $28.2K and leaving 1,350 shares worth $26K. The position accounts for ﹤0.01% of the portfolio, ranked #1004.

Shell Asset Management first reported a position in SRPT in Q4 2017 and has held it in 31 quarters since. The position peaked at $1.9M in Q2 2019. 320 funds tracked by Wall St. Rank hold SRPT as of Q3 2025.

  • Shell Asset Management held 1,350 shares of Sarepta Therapeutics worth $26K as of Q3 2025.
  • Shell Asset Management sold 1,584 Sarepta Therapeutics shares in Q3 2025, an estimated $28.2K.
  • Sarepta Therapeutics made up ﹤0.01% of Shell Asset Management's portfolio in Q3 2025, its #1004 holding.
  • Shell Asset Management first reported a position in Sarepta Therapeutics in Q4 2017 and has held it in 31 quarters since.
  • Shell Asset Management's Sarepta Therapeutics position peaked at $1.9M in Q2 2019.
  • 320 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q3 2025.

Based on Shell Asset Management's 13F filing for Q3 2025, filed 7 Nov 2025.